IVF.US INVO Fertility, Inc.
- Market cap
- USD 3.10M
- P/E
- 0.0x
- P/B
- 0.19x
- ROE
- -56.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is IVF.US undervalued?
Graham numberThe Graham number of INVO Fertility, Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
INVO Fertility, Inc. fundamental analysis
No fundamental analysis for INVO Fertility, Inc. yet.
INVO Fertility, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About INVO Fertility, Inc.
INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services and INVOcell Device segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. It also operates fertility clinics, including INVO Centers. The company was formerly known as…
Full company profileINVO Fertility, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
INVO Fertility, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 50.9K | 282K | 494K | 1.48M | 1.04M | 4.16M | 822K | 3.02M | 6.53M | 6.84M | 8.38M |
| Gross Profit | 35.8K | 230K | 404K | 1.34M | 949K | 4.02M | -28.6K | 1.09M | 2.87M | 2.53M | 2.69M |
| Operating Income | -2.11M | -640K | -2.63M | -1.79M | -5.51M | -5.22M | -10.6M | -6.77M | -8.13M | -5.84M | -5.76M |
| EBITDA | -2.11M | -678K | -2.63M | -1.76M | -5.48M | -5.22M | -10.8M | -6.88M | -7.14M | -3.51M | -12.7M |
| Net Income | -2.12M | -702K | -3.08M | -2.17M | -8.35M | -6.65M | -10.9M | -8.03M | -9.10M | -23.3M | -9.30M |
| EPS | -14,068 | -4,589 | -19,226 | -12,826 | -43,703 | -18,035 | -103,738 | -32,268 | -14,461 | -797 | -14 |
| Balance Sheet | |||||||||||
| Total Assets | 286K | 266K | 777K | 1.80M | 10.9M | 10.5M | 3.71M | 18.5M | 46.4M | 20.2M | 25.8M |
| Total Liabilities | 4.90M | 5.26M | 3.50M | 5.51M | 5.20M | 3.16M | 4.69M | 17.6M | 33.7M | 13.0M | 9.34M |
| Shareholders' Equity | -4.62M | -4.99M | -2.72M | -3.71M | 5.74M | 7.31M | -978K | 893K | 12.7M | 7.22M | 16.5M |
| Cash & Short-term Investments | 152K | 25.8K | 212K | 1.24M | 10.1M | 5.68M | 90.1K | 232K | 741K | 2.08M | 3.73M |
| Total Debt | 353K | 343K | 396K | 457K | 775K | 2.12M | 2.27M | 6.30M | 9.90M | 3.40M | 3.92M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -324K | -181K | -653K | 1.37M | -4.78M | -6.03M | -6.60M | -4.76M | -2.97M | -7.01M | -6.04M |
| Capital Expenditure | 15.7K | 0.00 | 19.4K | 64.8K | 88.9K | 455K | 12.7K | 445K | 184K | 43.4K | 801K |
| Free Cash Flow | -340K | -181K | -672K | 1.31M | -4.86M | -6.48M | -6.62M | -5.20M | -3.16M | -7.06M | -6.08M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -145.3% | -91.0% | - | -899.9% | -71.4% | -322.8% | -56.4% |
| ROA | -742.2% | -263.6% | -395.7% | -120.7% | -76.2% | -63.6% | -293.6% | -43.4% | -19.6% | -115.3% | -36.0% |
| Net Profit Margin | -4,173.3% | -248.9% | -622.2% | -146.4% | -804.7% | -160.0% | -1,324.8% | -266.0% | -139.3% | -340.9% | -111.0% |
| Debt to Equity | - | - | - | - | 0.13x | 0.29x | - | 7.06x | 0.78x | 0.47x | 0.24x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
INVO Fertility, Inc. dividends
INVO Fertility, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Oct 30, 2026.
Who owns INVO Fertility, Inc.
- Insiders 0.48%
- Institutions 9.23%
- Public & others 90.30%
- Shares outstanding 1.19M
- Free float 626K
Top funds holding IVF.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 9.30K | 0.19% | 0.00% | Sep 2026 |
Top institutions holding IVF.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Virtu Financial LLC | 63.2K | 1.37% | 0.00% | Jun 2026 |
| Essex, LLC | 45.8K | 0.99% | 0.00% | Sep 2026 |
| Scientech Research LLC | 32.3K | 0.70% | 0.00% | Jun 2026 |
| StoneX Group Inc | 15.7K | 0.34% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 11.5K | 0.25% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 8.16K | 0.18% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 53.00 | 0.00% | +1,666.67% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 38.00 | 0.00% | 0.00% | Jun 2026 |
| Integrated Wealth Concepts LLC | 8.00 | 0.00% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Mariner Wealth Advisors LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Armistice Capital, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
INVO Fertility, Inc. company profile
- Company name
- INVO Fertility, Inc.
- Ticker
- IVF.US
- Exchange
- USA Stocks
- Listed since
- May 21, 2012
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 40
- Fiscal year end
- December
- Address
- 5582 Broadcast Court, Sarasota, FL, United States, 34240
- Phone
- 978 878 9505
- Website
- invofertility.com
About INVO Fertility, Inc.
INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services and INVOcell Device segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. It also operates fertility clinics, including INVO Centers. The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025. INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.
INVO Fertility, Inc. management
3- Mr. Steven M. ShumCEO & Director · born 1971
- Ms. Terah KrigsvoldChief Financial Officer · born 1983
- Mr. Andrea GorenChief Business Officer · born 1967